Treatment options for relapsed acute promyelocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 3, 2003, Pages 521-534

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplant; Arsenic tetrasulphide; Arsenic trioxide; Autologous stem cell transplant; Gemtuzumab ozogamycin; PCR technology

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; ANTHRACYCLINE; ARSENIC DERIVATIVE; ARSENIC TETRASULFIDE; ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CALICHEAMICIN; CARMUSTINE; CEP 701; CYTARABINE; CYTOTOXIC AGENT; DEPSIPEPTIDE; DEXAMETHASONE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MIDOSTAURIN; MITOXANTRONE; MONOCLONAL ANTIBODY M 195; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; ARSENIC TETRA SULPHIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; COUGHING; DIARRHEA; DRUG MECHANISM; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER TOXICITY; LONG QT SYNDROME; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; NAUSEA AND VOMITING; NONHUMAN; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA SYNDROME; RASH; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; NEUROPATHY; RELAPSE; REVIEW;

EID: 0041828178     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00039-2     Document Type: Review

References (30)

1. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. GIMEMA-AIEOP Multicenter'AIDA' Trial. Blood 1998; 92: 784-789.
2. Jurcic JG, Nimer SD, Scheinberg DA et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651-2656.
3. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
4. Estey EH, Giles FJ, Kantarjian H et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 2230-2235.
5. Bolufer P, Lo Coco F, Grimwade D et al. Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica 2001; 86: 570-576.
6. Burenett AK, Grimwade D, Solomon E et al. Presenting white cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 1999; 93: 4131.
7. Shao W, Fanelli M, Ferrara FF et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute 1998; 90: 24-133.
8. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology 2001; 19: 3852-3860.
9. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in II newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 33 15-3324.
10. Soignet SL, Frankel SR, Douter D et al. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): the US experience. Proceedings of the Joint International Congress on APL and Differential Therapy 2001; 57. abstract P7.11.
11. Unnikrishnan D, Dutcher JP. Varshneya N et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-1516.
12. Westervelt P, Brown RA, Adkins DR et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-271.
13. Singer JW. Cardiac toxicity of arsenic trioxide. Blood 2001; 98: 1633. (letter).
14. Jurcic JG, DeBlasio T, Dumont L et al. Molecular remission induction with retinoic acid and tinti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clinical Cancer Research 2000; 6: 372-380.
15. Estey EH, Giles FJ, Beran M et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
16. Tallman MS, Nabhan C, Feusner JH & Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
17. Estey E, Thall PF, Pierce S et al. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. Journal of Clinical Oncology 1997; 15: 483-490.
18. Sanz MA, Lo Coco F, Martin G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
19. Petti MC, Pinazzi MB, Diverio D et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). British Journal of Haematology 2001; 115: 63-65.
20. Lo Coco F, Diverio D, Cimino G et al. Mylotarg (gemtuzumab ozogamicin) for molecularly relapsed APL. Proceedings of the Joint International Congress on APL and Differential Therapy 2001; abstract P7.26.
21. Sanz MA, Arcese W, de la Rubia J et al. Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: a survey of the European blood and marrow transplantation group (EBMT). Blood 2000; 96. abstract#2247.
22. Thomas X, Dombret H, Stamatoulas A et al. Acute promyelocytic leukemia (APL): autologous stem cell transplantation (SCT) in second complete remission (CR2). Proceedings of the Joint International Congress on APL and Differential Therapy 2001; abstract P7.8.
23. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90: 1321-1325.
24. Sanz MA, de la Rubia J, Bonanad S et al. Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft? Leukemia 1998; 12: 992-995.
25. Specchia G, Lo Coco F, Vignetti M et al. Extramedullary involvement in relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. Journal of Clinical Oncology 2001; 19: 4023-4028.
26. 3) ± all-trans retinoic acid (ATRA): the French As98 Study. Blood 2000; 96. abstract #3578.
27. Lu DP, Qiu JY, Jiang B et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 2136-2143.
28. Noguera NI, Breccia M, Divona M et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189.
29. He LZ, Tolentino T, Grayson P et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. Journal of Clinical Investigation 2001; 108: 1321-1330.
30. Warrell Jr. RP, He LZ, Richon V et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute 1998; 90: 1621-1625.